CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones.
Second Quarter & Recent Corporate Highlights
- $50 Million Strategic Partnership Secured – All contingencies finalized with Quazar Investment following incorporation of NuroMENA Holdings under Abu Dhabi Global Market (ADGM). This partnership will launch an advanced GCC & MENA clinical trials platform and expand NTHI’s global footprint.
- Non-Dilutive NIH Funding – Awarded $2.5 million in STTR grants to advance NEO212 for gliomas and leukemia, underscoring strong scientific validation and external funding support.
- Technology Expansion – Signed definitive agreement to acquire AI, 3D bioprinting, and quantum modeling IP portfolio from Dr. Ishwar K. Puri.
- Media & Market Visibility –
- Featured on Yahoo Finance’s Trader Talk podcast discussing AI and biotech’s role in brain cancer treatment.
- Entered a 12-part national TV and media campaign with New to The Street, including commercials, earned media, and billboards.
- Executive Chairman interviewed live by …